AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 32 min read$APMD

Molnar Dennis Patrick sold (to issuer) 58,014 shares of APMD

Molnar Dennis Patrick (President) sold (to issuer) 58,014 shares of Apnimed, Inc. (APMD) on 2026-08-03.

Original reporting
SEC EDGAR · Molnar Dennis Patrick
Published Aug 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:14 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$APMD
Neutral
low confidence
Mentioned
$APMD
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APMDNeutralLow
01

Why it matters

The filing updates insider ownership (ending with 0 shares) but provides no price or total value, limiting inference about valuation or near-term fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a major repricing without additional company news.

03

What to watch

The sale is coded as “sale to issuer,” which can reflect buyback participation or other structured liquidity events rather than a directional bearish signal.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-03, after-hours/late session timing for traders to note.

Background

This is an SEC Form 4 insider transaction for Apnimed, Inc. (APMD) reported on 2026-08-03.

Company-level read

Ticker impact

$APMDNeutralLow confidence
Context

Apnimed insider Molnar Dennis Patrick, President, sold 58,014 shares to the issuer on 2026-08-03 under Form 4.

Expected impact

Low likelihood of a sustained price move based solely on this filing.

Evidence & confidence

The transaction is an insider sale with no disclosed price/value and no 10b5-1 plan, but the filing alone provides no new operating or financial catalyst.

Market effects

Sector

No clear sector read-through from a single insider sale without disclosed financial details.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even without disclosed price, a large insider sale can be interpreted as reduced confidence, especially since no 10b5-1 plan is cited.

Key entities

  • issuer
    Apnimed, Inc.

    Company whose insider transaction is reported on Form 4.

  • insider
    Molnar Dennis Patrick

    President who sold 58,014 shares to the issuer on 2026-08-03.

Read at source← All news

Related articles

AUG 3
$APMDMedAI 8/10

Apnimed raises $220.8M in upsized Nasdaq IPO

Apnimed, Inc. (Nasdaq: APMD) priced and closed an upsized Nasdaq IPO raising $220.8M in gross proceeds. It sold 13.8M shares at $16.00 each, including 1.8M from the underwriters’ overallotment option. Shares began trading July 31, 2026. The company develops AD109 for obstructive sleep apnea, with two Phase 3 trials completed and an NDA PDUFA goal date of Feb. 28, 2027.

investing.com2 min
AUG 1
$APMDMedAI 8/10

Apnimed Soars 56% in Nasdaq Debut After $192M IPO

Apnimed Inc. (Nasdaq: APMD) jumped 56% in its Nasdaq debut after pricing an enlarged $192M IPO. It sold 12M shares at $14-$16, closing at $25. The company reported $84.8M revenue and $67.7M net income for the quarter ended March 31. It is developing Oxnimbi for obstructive sleep apnea, with an FDA marketing request filed in April.

briefs.co5 min
JUL 31
$APMDMedAI 8/10

Apnimed Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- Apnimed, Inc. ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a price to the public of $16.00 per share.

prnewswire.com2 min
JUL 31
$APMDMedAI 8/10

Apnimed prices IPO at $16 per share, raising $192 million

S. Korea’s KOSPI surges over 16% as Samsung, SK Hynix rebound after Wall St rally Apnimed, Inc., a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, has priced its initial public offering of 12 million shares of common stock at $16.00 per share, according to a press release issued July 30, 2026. The company expects to raise $192 million in gross proceeds before deducting underwriting discounts, commissions, and offering expenses.

investing.com4 min